Pulmonary vascular disease & thromboembolism
Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism in patients with inflammatory joint disease—results from the nationwide Norwegian Cardio-rheuma registry
Authors' conclusion
Pulmonary embolism rates appeared to be higher in IJD than among non-IJD subjects in our study. Traditional NSAIDs may protect against PE in IJD patients, while coxibs may associated with increased PE risk.
Study context
- Population
- Adults in the whole Norwegian population, including patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA)median follow-up 9.0 years
- Participants
- 4,660,475 adults
- Exposure
- tNSAID or coxib use vs non-use; Inflammatory joint diseases (IJD) vs non-IJD
- IJDn = 74,001
- Outcome
- Pulmonary embolism (PE) associated with tNSAID and coxib use
Methodological detailsindividual-level registry data
- Individual-level registry data
Main finding
As reported in the abstract
PE during NSAID use (IRR)
Incidence rate ratio (95% CI)P value
IJDvs Non-IJDtNSAID use
0.78(0.64–0.94)
P = 0.010Non-IJDtNSAID use
1.68(1.61–1.76)
P < 0.001IJDvs Non-IJDcoxib use
1.75(1.10–2.79)
P = 0.018Non-IJDcoxib use
2.80(2.47–3.18)
P < 0.001Observational data: associations, not effects.
Further findings
PE risk, IJD vs non-IJD · age and sex adjusted
HR 1.57
Original publication
Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism in patients with inflammatory joint disease—results from the nationwide Norwegian Cardio-rheuma registry. Eur Heart J Cardiovasc Pharmacother. Published 25 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →